tetano
Editor, Senior Moderator
Clin Infect Dis. 2018 Sep 11. doi: 10.1093/cid/ciy775. [Epub ahead of print]
[h=1]Influenza Vaccine Effectiveness in the United States during the 2016-2017 Season.[/h] Flannery B[SUP]1[/SUP], Chung JR[SUP]1[/SUP], Monto AS[SUP]2[/SUP], Martin ET[SUP]2[/SUP], Belongia EA[SUP]3[/SUP], McLean HQ[SUP]3[/SUP], Gaglani M[SUP]4[/SUP], Murthy K[SUP]4[/SUP], Zimmerman RK[SUP]5[/SUP], Nowalk MP[SUP]5[/SUP], Jackson ML[SUP]6[/SUP], Jackson LA[SUP]6[/SUP], Rolfes MA[SUP]1[/SUP], Spencer S[SUP]1[/SUP], Fry AM[SUP]1[/SUP]; US Flu VE Investigators.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] In recent influenza seasons, the effectiveness of inactivated influenza vaccines against circulating A(H3N2) virus has been lower than against A(H1N1)pdm09 and B viruses, even when circulating viruses remained antigenically similar to vaccine components.
[h=4]Methods:[/h] During the 2016-2017 influenza season, vaccine effectiveness (VE) across age groups and vaccine types was examined among outpatients with acute respiratory illness at 5 US sites using a test-negative design that compared the odds of vaccination among reverse transcription polymerase chain reaction-confirmed influenza positives and negatives.
[h=4]Results:[/h] Among 7083 enrollees, 1342 (19%) tested positive for influenza A(H3N2), 648 (9%) were positive for influenza B (including B/Yamagata, n = 577) and 5040(71%) were influenza negative. Vaccine effectiveness was 40% (95% confidence interval [CI], 32% to 46%) against any influenza virus, 33% (95%CI, 23% to 41%) against influenza A(H3N2) viruses and 53% (95%CI, 43% to 61%) against influenza B viruses.
[h=4]Conclusions:[/h] The 2016-2017 influenza vaccines provided moderate protection against any influenza among outpatients, but were less protective against influenza A(H3N2) viruses than B viruses. Approaches to improving effectiveness against A(H3N2) viruses are needed.
PMID: 30204854 DOI: 10.1093/cid/ciy775
[h=1]Influenza Vaccine Effectiveness in the United States during the 2016-2017 Season.[/h] Flannery B[SUP]1[/SUP], Chung JR[SUP]1[/SUP], Monto AS[SUP]2[/SUP], Martin ET[SUP]2[/SUP], Belongia EA[SUP]3[/SUP], McLean HQ[SUP]3[/SUP], Gaglani M[SUP]4[/SUP], Murthy K[SUP]4[/SUP], Zimmerman RK[SUP]5[/SUP], Nowalk MP[SUP]5[/SUP], Jackson ML[SUP]6[/SUP], Jackson LA[SUP]6[/SUP], Rolfes MA[SUP]1[/SUP], Spencer S[SUP]1[/SUP], Fry AM[SUP]1[/SUP]; US Flu VE Investigators.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] In recent influenza seasons, the effectiveness of inactivated influenza vaccines against circulating A(H3N2) virus has been lower than against A(H1N1)pdm09 and B viruses, even when circulating viruses remained antigenically similar to vaccine components.
[h=4]Methods:[/h] During the 2016-2017 influenza season, vaccine effectiveness (VE) across age groups and vaccine types was examined among outpatients with acute respiratory illness at 5 US sites using a test-negative design that compared the odds of vaccination among reverse transcription polymerase chain reaction-confirmed influenza positives and negatives.
[h=4]Results:[/h] Among 7083 enrollees, 1342 (19%) tested positive for influenza A(H3N2), 648 (9%) were positive for influenza B (including B/Yamagata, n = 577) and 5040(71%) were influenza negative. Vaccine effectiveness was 40% (95% confidence interval [CI], 32% to 46%) against any influenza virus, 33% (95%CI, 23% to 41%) against influenza A(H3N2) viruses and 53% (95%CI, 43% to 61%) against influenza B viruses.
[h=4]Conclusions:[/h] The 2016-2017 influenza vaccines provided moderate protection against any influenza among outpatients, but were less protective against influenza A(H3N2) viruses than B viruses. Approaches to improving effectiveness against A(H3N2) viruses are needed.
PMID: 30204854 DOI: 10.1093/cid/ciy775